Ginkgolic acid C17:1

Name: Ginkgolic acid C17:1
Brand: MedChemExpress
SKU: HY-N2116
Rating: 4.5 (1 reviews)

Cat. No.: HY-N2116 Purity: 99.90%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ginkgolic acid C17:1 is a fatty acid synthase (FAS) inhibitor with an IC₅₀ of 10.5 µM. Ginkgolic acid C17:1 shows anti-tumor activity by inhibiting the phosphorylation of STAT3 and inducing apoptosis. Ginkgolic acid C17:1 can block the interaction between S-RBD and ACE2, and has anti-SARS-CoV-2-S pseudovirus activity. Ginkgolic acid C17:1 inhibits the biofilm formation of enterohemorrhagic Escherichia coli and Staphylococcus aureus.

For research use only. We do not sell to patients.

Ginkgolic acid C17:1 Chemical Structure

CAS No. : 111047-30-4

Size	Price	Stock	Quantity
5 mg	USD 269	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 457	In-stock	Estimated Time of Arrival: December 31
50 mg		Get quote
100 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Ginkgolic acid C17:1:

Ginkgolic acid C17:1 (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All STAT Isoform Specific Products:

View All Isoforms

STAT3 STAT5 STAT6 STAT1

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

STAT3

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	29.2 μg/mL Compound: 6, phenolic acid C17:1	Growth inhibition of human A549 cells after 2 days by SRB assay Growth inhibition of human A549 cells after 2 days by SRB assay	[PMID: 9677265]
HCT-15	IC₅₀	8.39 μg/mL Compound: 6, phenolic acid C17:1	Growth inhibition of human HCT15 cells after 2 days by SRB assay Growth inhibition of human HCT15 cells after 2 days by SRB assay	[PMID: 9677265]
HT1197	IC₅₀	28.14 μg/mL Compound: 6, phenolic acid C17:1	Growth inhibition of human HT1197 cells after 2 days by SRB assay Growth inhibition of human HT1197 cells after 2 days by SRB assay	[PMID: 9677265]
MCF7	IC₅₀	5.06 μg/mL Compound: 6, phenolic acid C17:1	Growth inhibition of human MCF7 cells after 2 days by SRB assay Growth inhibition of human MCF7 cells after 2 days by SRB assay	[PMID: 9677265]
SK-OV-3	IC₅₀	> 50 μg/mL Compound: 6, phenolic acid C17:1	Growth inhibition of human SKOV3 cells after 2 days by SRB assay Growth inhibition of human SKOV3 cells after 2 days by SRB assay	[PMID: 9677265]

In Vitro

Ginkgolic acid C17:1 (30-50 μM; 24 h) reduces the viability of U266 cells with an IC₅₀ about 64 µM, but has no effect on PBMCs^[1].
Ginkgolic acid C17:1 (30-50 μM; 1.5-24 h) inhibits the phosphorylation of STAT3, up-regulates the expression of PTEN and SHP-1, and induces apoptosis in multiple myeloma cells^[1].
Ginkgolic acid C17:1 (10-500 μM; 25 h) inhibits SARS-CoV-2-S pseudovirus in hACE2/HEK293T cells with an IC₅₀ of 79.43 μM and the maximum half cytotoxic concentration (CC₅₀) of 130.8 μM^[2].
Ginkgolic acid C17:1 (1-20 μg/mL; 24 h) significantly and dose-dependent inhibits the biofilm formation of enterohemorrhagic Escherichia coli (EHEC) and Staphylococcus aureus, but did not affect the growth of EHEC cells^[3].
Ginkgolic acid C17:1 (0-30 μg/mL; 0-72 h) inhibits SMMC-7721 cells with an IC₅₀ of 8.5 μg/mL, and induces apoptosis and inhibits cell migration^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:	U266 cells
Concentration:	30 and 50 μM
Incubation Time:	24 h
Result:	Reduced cell viability of U266 in a concentration-dependent manner.

Western Blot Analysis^[1]

Cell Line:	U266 cells
Concentration:	30 and 50 μM
Incubation Time:	1.5 and 3 h
Result:	Substantially suppressed phosphorylation of STAT3 in a dose- and time-dependent manner.

Western Blot Analysis^[4]

Cell Line:	U266 cells
Concentration:	0, 5, 10, 20 and 30 μg/mL
Incubation Time:	0, 24, 48 and 72 h
Result:	Increased the Bax/Bcl-2 ratio by significantly increasing the expression of the pro-apoptotic protein Bax.

Molecular Weight

374.56

Formula

C₂₄H₃₈O₃

CAS No.

111047-30-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)C1=C(O)C=CC=C1CCCCCCCCC/C=C\CCCCCC

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (266.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6698 mL	13.3490 mL	26.6980 mL
5 mM	0.5340 mL	2.6698 mL	5.3396 mL
10 mM	0.2670 mL	1.3349 mL	2.6698 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (6.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.90%

Select Batch:

Data Sheet (276 KB) SDS (393 KB)

COA (240 KB) HNMR (239 KB) LCMS (286 KB)

Handling Instructions (2659 KB)

References

[1]. Baek SH, et al. Ginkgolic Acid C 17:1, Derived from Ginkgo biloba Leaves, Suppresses Constitutive and Inducible STAT3 Activation through Induction of PTEN and SHP-1 Tyrosine Phosphatase. Molecules. 2017 Feb 13;22(2). pii: E276. [Content Brief]

[2]. Xiang Y, et al. Ginkgolic acids inhibit SARS-CoV-2 and its variants by blocking the spike protein/ACE2 interplay. Int J Biol Macromol. 2023 Jan 31;226:780-792. [Content Brief]

[3]. Lee JH, et al. Ginkgolic acids and Ginkgo biloba extract inhibit Escherichia coli O157:H7 and Staphylococcus aureus biofilm formation. Int J Food Microbiol. 2014 Mar 17;174:47-55. [Content Brief]

[4]. Yang XM, et al. Thermal stability of ginkgolic acids from Ginkgo biloba and the effects of ginkgol C17:1 on the apoptosis and migration of SMMC7721 cells. Fitoterapia. 2014 Oct;98:66-76. [Content Brief]

[5]. Oh J, et al. Inhibition of fatty acid synthase by ginkgolic acids from the leaves of Ginkgo biloba and their cytotoxic activity. J Enzyme Inhib Med Chem. 2013 Jun;28(3):565-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.6698 mL	13.3490 mL	26.6980 mL	66.7450 mL
	5 mM	0.5340 mL	2.6698 mL	5.3396 mL	13.3490 mL
	10 mM	0.2670 mL	1.3349 mL	2.6698 mL	6.6745 mL
	15 mM	0.1780 mL	0.8899 mL	1.7799 mL	4.4497 mL
	20 mM	0.1335 mL	0.6674 mL	1.3349 mL	3.3372 mL
	25 mM	0.1068 mL	0.5340 mL	1.0679 mL	2.6698 mL
	30 mM	0.0890 mL	0.4450 mL	0.8899 mL	2.2248 mL
	40 mM	0.0667 mL	0.3337 mL	0.6674 mL	1.6686 mL
	50 mM	0.0534 mL	0.2670 mL	0.5340 mL	1.3349 mL
	60 mM	0.0445 mL	0.2225 mL	0.4450 mL	1.1124 mL
	80 mM	0.0334 mL	0.1669 mL	0.3337 mL	0.8343 mL
	100 mM	0.0267 mL	0.1335 mL	0.2670 mL	0.6674 mL